Clinical Trials Lab Tests SubscribeHome Dengue Flu Measles RSV STD Travel Vaccines

BREAKING NEWS: Second-Generation Anti-Cancer Vaccine Targets Melanoma

March 26, 2024 • 9:29 am CDT

Defence Therapeutics Inc. has announced the successful testing of a second-generation anti-cancer vaccine, ARM-002TM, using its lead anti-cancer molecule AccuTOX®.

When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM led to an 80% complete response when combined with the anti-PD-1 immune checkpoint inhibitor.

The ARM-002TM vaccine was tested in vivo in the context of melanoma.

Mr. Sébastien Plouffe, Chief Executive Officer and Director of Defence Therapeutics, commented on the success of the testing, stating, ‘AccuTOX® is an amazing molecule! AccuTOX® has the capacity to trigger cancer cell death when used as a direct cancer injectable, and AccuTOX®, the same molecule, converts mesenchymal stromal cells into potent antigen-presenting cells capable of priming potent anti-tumoral responses using 10-fold lower antigen preparation.’

Vaccination can stimulate specific immune responses capable of potentially curing established tumors compared to current anti-cancer strategies. In addition, developed immune cells can lead to a long-lasting memory response capable of further protecting the patient from subsequent cancer relapses, says the company.

According to Data Bridge Market Research, this vaccine segment is expected to reach revenues of about $900 billion by 2029.

Our Trust Standards: Medical Advisory Committee

BIG STORIES

• U.S. Unprepared for Next Smallpox Outbreak
• Yellow Fever Fatalities Reactivate in The Americas
• Puerto Rico’s Mosquitoes Continue Carrying Dengue and Zika Viruses
• Pharmacies Offer Protein-Based COVID-19 Vaccine Where Needed
• Enhancing Indoor Ventilation Reduces Respiratory Virus Risk
• Immunotherapy Drugs Project 18% CAGR
• Can Vaccines Empower World Tuberculosis Day
• Over 1,100 Zika Cases Confirmed in 2024
• Are New Tuberculosis Vaccines Really Needed
• mRNA Skin Cancer Vaccine Candidate Launches Phase Two Study

CONTENT POLICY

Please do not reproduce this content in part or in whole without permission. Share the page URL which directs to the original content.

DISCLAIMER

Precision Vax LLC websites do not provide medical advice, diagnosis, treatment, or prescriptions. Read our terms of use for more info.

SITE LINKS

• Contact
• Terms
• Privacy
• About
• Advisory
• Copyright ©2024 Precision Vax LLC